SC · State regulatory reference
South Carolina.
Moderate
South Carolina permits telemedicine under the Telemedicine Act, S.C. Code § 40-47-37, which lets a licensee establish a physician-patient relationship and prescribe without a prior in-person visit if the standard of care can be met remotely, subject to a medical-history interview and a bar on prescribing where an in-person exam is necessary. Compounding under S.C. Code Title 40 Ch. 43 and Regulations Ch. 99 (Board of Pharmacy/LLR) imposes no state-specific GLP-1 rule and tracks FDA policy; per the Board's May 2025 newsletter, FDA enforcement discretion for 503A compounding of semaglutide and tirzepatide has ended. No documented SC board enforcement targeting peptides or GLP-1 compounding was found.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Under S.C. Code § 40-47-37, an initial visit and prescribing may occur via telehealth without a prior in-person exam if the physician can meet the standard of care remotely, though prescribing is barred where an in-person exam is necessary and most Schedule II/III telehealth prescribing is restricted.
Compounding
SC follows FDA policy on GLP-1 compounding rather than a state-specific rule; the Board of Pharmacy's May 2025 newsletter notes FDA enforcement discretion has ended for 503A compounding of semaglutide and tirzepatide. Compounding is regulated under S.C. Code Title 40 Ch. 43 and Regulations Ch. 99.
Sources